237 related articles for article (PubMed ID: 16709308)
1. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
4. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
5. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
6. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
7. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents.
Pollock RF; Valentine WJ; Goodall G; Brändle M
Swiss Med Wkly; 2010; 140():w13103. PubMed ID: 21110238
[TBL] [Abstract][Full Text] [Related]
9. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
10. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
11. Self-monitoring of blood glucose in type 2 diabetes: systematic review.
Clar C; Barnard K; Cummins E; Royle P; Waugh N;
Health Technol Assess; 2010 Mar; 14(12):1-140. PubMed ID: 20226138
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
14. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.
Malanda UL; Welschen LM; Riphagen II; Dekker JM; Nijpels G; Bot SD
Cochrane Database Syst Rev; 2012 Jan; 1():CD005060. PubMed ID: 22258959
[TBL] [Abstract][Full Text] [Related]
15. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
Palmer AJ; Valentine WJ; Ray JA; Foos V; Lurati F; Smith I; Lammert M; Roze S
Curr Med Res Opin; 2007 Apr; 23(4):895-901. PubMed ID: 17407646
[TBL] [Abstract][Full Text] [Related]
16. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
Tunis SL; Minshall ME
Am J Manag Care; 2008 Mar; 14(3):131-40. PubMed ID: 18333705
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
[No Abstract] [Full Text] [Related]
18. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
19. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
[TBL] [Abstract][Full Text] [Related]
20. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]